Pedro Henrique Destro1, Geraldo Medeiros Junior2, Joyce Moreira Camargo3, Alphonse Laya4, Valquiria Bueno5*

1Undergraduate Student of Biomedicine, UNIFESP Federal University of São Paulo; 2Undergraduate Student of Biomedicine, UNIP Paulista University; 3Master Student at Department of Microbiology, Parasitology and Immunology, UNIFESP Federal University of São Paulo; 4Post doctor at Department of Microbiology, Parasitology and Immunology, UNIFESP Federal University of São Paulo; 5Associate Professor at Department of Microbiology, Parasitology and Immunology, UNIFESP Federal University of São Paulo.

The first report of patients with the SARS-CoV-2 was in Wuhan on December 2019. In few months the virus was disseminated around the world and has caused millions of deaths. A striking and recurrent finding was the more severe disease and increased numbers of fatal cases in old adults. Vaccines were developed in a record period of time and since then a massive program of vaccination has been installed in several countries. Nevertheless, the decrease in the levels of specific antibody after six months of the first dose in young adults and the reports of fatal cases in vaccinated older patients have suggested that a 3rd dose of vaccine is required. From the first report until now it has been clear that the immune system plays an important role in the disease development and patient outcome. Our group showed recently that healthy old individuals present changes in the immune system that have been reported as immunosenescence and inflammageing. Therefore, our aim was to correlate the findings obtained in healthy old adults with cases of COVID-19 from literature in order to identify possible common factors. The further understanding of how the changes occurring in the immune system during the ageing process can affect the response to SARS-CoV-2 virus could contribute for the development of vaccines or more specific therapies to the aged population.

Keywords: SARS-CoV-2, COVID-19, Ageing, Immunosenescence, Inflammageing

Free Full-text PDF

How to cite this article:
Pedro Henrique Destro, Geraldo Medeiros Junior, Joyce Moreira Camargo, Alphonse Laya, Valquiria Bueno. COVID-19 AND AGEING-RELATED EVENTS. International Journal of Aging Research, 2021, 4:91. DOI: 10.28933/ijoar-2021-09-2605


1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, Eng-land) 2020; 395:497–506
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wu-han, China: a descriptive study. Lancet 2020; 395:507–513
3. Zarocostas J. What next for the coronavirus re-sponse? Lancet 2020; 395:401
4. National Health Commission of PRC. Daily Briefing on Novel Coronavirus Cases in China. (2020). Available online at: http://ennhcgovcn/2020-02/23/c_76779htm.
5. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVID-19: Fo-cus on Severity and Mortality. Front Public Health. 2020; 8:152.
6. World Health Organization. (2020, March 3). Corona-virus disease 2019 (COVID-19) Situation Report – 43. Available from:
/situation-reports/20200303-sitrep-43-covid-19. Ac-cessed 4 Mar 2020.
7. Buckner FS, McCulloch DJ, Atluri V, Blain M, McGuffin SA, Nalla AK, et al. Clinical Features and Outcomes of 105 Hospitalized Patients With COVID-19 in Seattle, Washington. Clin Infect Dis 2020;71(16):2167-2173.
8. Working group for the surveillance and control of COVID-19 in Spain; Members of the Working group for the surveillance and control of COVID-19 in Spain. The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020. Euro Surveill 2020; 25 (50): 2001431.
9. Conheça a faixa etária dos mortos por covid-19 no Brasil e em mais 4 países Internet.. Poder360. 2021 cited 2021 Jul 25.. Available from:
10. Alves AS, Bueno V. Immunosenescence: participa-tion of T lymphocytes and myeloid-derived sup-pressor cells in aging-related immune response changes. Einstein (Sao Paulo) 2019;17(2):eRB4733.
11. Alves AS, Ishimura ME, Duarte YAO, Bueno V. Pa-rameters of the Immune System and Vitamin D Levels in Old Individuals. Front Immunol 2018; 9: 1122.
12. Naeim F, Rao PN, Song SX, Grody WW. Atlas of hematopathology, morphology, immunophenotype, cytogenetics, and molecular approaches. Academic Press, New York, NY, 2013.
13. Chmielewski PP et al. The association between total leukocyte count and longevity: Evidence from lon-gitudinal and cross-sectional data. Annals of Anat-omy 2016; 204: 1-10
14. Geiger H, de Haan G, Carolina Florian M. The ageing haematopoietic stell cell compartment. Nature Rev Immunol 2013; 5: 376-389
15. Chung SS, Park CY. Aging, hematopoiesis, and the myelodysplastic syndromes. Blood Advances 2017; 1: 2572-2578
16. Zhang L et al. Molecular and cellular mechanisms of aging in hematopoietic stem cells and their niches. J Hematol Oncol 2020; 13: 1-22
17. Lynch HE, Goldberg GL, Chidgey A, et al. Thymic involution and immune reconstitution. Trends Im-munol 2009; 30: 366-373
18. Rui L et al. Clinical observations in very old patients with COVID-19 in Wuhan. Geriatr and Gerontol Int 2020; 20: 709-714
19. Lui J et al. Lymphopenia predicted illness severity and recovery in patients with COVID-19: A sin-gle-center, retrospective study. PLos One 2020; 15: 1-15
20. Gao S et al. Risk factors influencing the prognosis of elderly patients infected with COVID-19: a clinical retrospective study in Wuhan, China. Aging 2020; 12: 12504-12516 doi: 10.18632/aging.103631.
21. Chinn IK, Blackburn CC, Manley NR et al. Changes in primary lymphoid organs with aging. Semin Im-munol 2012; 24(5): 309-20.
22. Qin L, Jing X, Qiu Z, Cao W, Jiao Y, Routy JP, et al. Aging of immune system: Immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults. Aging (Albany NY) 2016; 8(5): 848-59.
23. Goronzy JJ, Fang F, Cavanagh MM, Qi Q, Weyand CM. Naive T cell maintenance and function in human aging. J Immunol 2015; 194(9): 4073-4080
24. Goronzy JJ, Weyand CM. Successful and Maladap-tive T Cell Aging. Immunity 2017; 46(3): 364-378
25. Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 2020; 183(4): 996-1012
26. Jin M, Shi N, Wang M, Shi C, Lu S, Chang Q, et al. CD45: a critical regulator in immune cells to predict severe and non-severe COVID-19 patients. Aging (Albany NY) 2020; 12(20): 19867-19879
27. Bellesi S, Metafuni E, Hohaus S, Maiolo E, Mar-chionni F, D’Innocenzo S, et al. Increased CD95 (Fas) and PD-1 expression in peripheral blood T lympho-cytes in COVID-19 patients. Br J Haematol 2020; 191(2): 207-211.
28. Townsend L, Dyer AH, Naughton A, Kiersey R, Holden D, Gardiner M, et al. Longitudinal Analysis of COVID-19 Patients Shows Age-Associated T Cell Changes Independent of Ongoing Ill-Health. Front Immunol 2021; 12: 676932.
29. Westmeier J, Paniskaki K, Karaköse Z, Werner T, Sutter K, Dolff S, et al. Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. mBio 2020; 11(5): e02243-20.
30. Murillo-Ortiz B, Albarrán-Tamayo F, López-Briones S, Martínez-Garza S, Benítez-Bribiesca L, Arenas-Aranda D. Increased telomere length and proliferative po-tential in peripheral blood mononuclear cells of adults of different ages stimulated with concanavalin A. BMC Geriatr 2013; 13: 99
31. Neidleman J, Luo X, Frouard J, Xie G, Gill G, Stein ES, et al. SARS-CoV-2-Specific T Cells Exhibit Pheno-typic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential. Cell Rep Med 2020; 1(6): 100081
32. Avendaño-Ortiz J, Lozano-Rodríguez R, Mar-tín-Quirós A, Maroun-Eid C, Terrón V, Valentín J, et al. Proteins from SARS-CoV-2 reduce T cell proliferation: A mirror image of sepsis. Heliyon 2020; 6(12): e05635.
33. Pawelec G, Picard E, Bueno V, Verschoor CP, Os-trand-Rosenberg S. MDSCs, ageing and inflam-mageing. Cell Immunol 2021; 362: 104297
34. Agrati C, Sacchi A, Bordoni V, Cimini E, Notari S, Grassi G, et al. Expansion of myeloid-derived sup-pressor cells in patients with severe coronavirus disease (COVID-19). Cell Death Differ 2020; 27(11): 3196-3207.
35. Sacchi A, Grassi G, Bordoni V, Lorenzini P, Cimini E, Casetti R, et al. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death Dis 2020; 11(10): 921
36. Falck-Jones S, Vangeti S, Yu M, Falck-Jones R, Cagigi A, Badolati I, et al. Functional monocytic my-eloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. J Clin Invest 2021; 131(6): e144734.
37. Tomić S, Đokić J, Stevanović D, Ilić N, Gru-den-Movsesijan A, Dinić M, et al. Reduced Expres-sion of Autophagy Markers and Expansion of Mye-loid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe COVID-19 Patients. Front Immunol 2021; 12: 614599.
38. Tomić S, Đokić J, Stevanović D, Ilić N, Gru-den-Movsesijan A, Dinić M, et al. Reduced Expres-sion of Autophagy Markers and Expansion of Mye-loid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe COVID-19 Patients. Front Immunol 2021; 12: 614599

Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details).

This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.